Clinical Trial Update: Study of OB-002 in Patients With Refractory Metastatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 study of OB-002 in various metastatic cancers has been withdrawn from clinical trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cancer
• Colorectal Cancer
• Gastric Cancer
• Pancreatic Cancer
• Urothelial Carcinoma

Drugs mentioned

• OB-002

Snippet

Sponsor: Orion Biotechnology Polska Sp. z o.o. | Conditions: Metastatic Cancer, Metastatic Colorectal Cancer | Phase 1 | Status: WITHDRAWN